| Total 939 Paclitaxel
related US patents (from
US Patent & Trademark Office)
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
No. 501 - 600 Paclitaxel Patents:
|
PAT. NO. |
|
Title |
| 501 |
6,245,750 |
 |
Enzyme
catalyzed therapeutic agents |
| 502 |
6,245,349 |
|
Drug
delivery compositions suitable for intravenous injection |
| 503 |
6,242,614 |
|
Semi-synthesis
of paclitaxel using dialkyldichlorosilanes |
| 504 |
6,242,478 |
|
Five
member ring sulfenate esters and thiosulfinate esters |
| 505 |
6,242,469 |
|
Synthesis
of epothilones, intermediates thereto, analogues and uses thereof |
| 506 |
6,239,181 |
|
Method
for preventing and treating peripheral neurophathy by administering
selegiline |
| 507 |
6,235,782 |
|
Method
for treating a patient with neoplasia by treatment with a platinum
coordination complex |
| 508 |
6,235,776 |
|
Method
for treating a patient with neoplasia by treatment with a paclitaxel
derivative |
| 509 |
6,235,761 |
|
Compound,
composition and method for treating cancer |
| 510 |
6,235,748 |
|
Oxo-substituted
compounds, process of making, and compositions and methods for
inhibiting parp activity |
| 511 |
6,235,714 |
|
Methods
for identifying inducers and inhibitors of proteolytic antibodies,
compositions and their uses |
| 512 |
6,232,477 |
|
Methods
of preparing new taxoids and pharmaceutical compositions containing
them |
| 513 |
6,232,340 |
|
Vanadium
complexes and derivatives thereof and methods related thereto |
| 514 |
6,231,600 |
|
Stents
with hybrid coating for medical devices |
| 515 |
6,231,590 |
|
Bioactive
coating for vaso-occlusive devices |
| 516 |
6,231,536 |
|
Method
and compositions for treatments of cancers |
| 517 |
6,229,027 |
|
Process
for manufacturing paclitaxel and 13-acetyl-9-dihydrobaccatin IV |
| 518 |
6,229,016 |
|
Method
for treating tumors using 2-aryl-naphthyridin-4-ones |
| 519 |
6,228,843 |
|
Method
of using PKC inhibiting compounds to treat vascular disease |
| 520 |
6,228,393 |
|
Drug
delivery via therapeutic hydrogels |
| 521 |
6,225,463 |
|
Synthesis
of new .beta.-lactams |
| 522 |
6,225,353 |
|
Method
and composition for selectively inhibiting melanoma |
| 523 |
6,225,325 |
|
Use
of alkylated iminosugars to treat multidrug resistance |
| 524 |
6,224,865 |
|
Suppression
of inhibitors |
| 525 |
6,224,847 |
|
Process
for the extraction of a compound by a fluorocarbon compound |
| 526 |
6,222,053 |
|
Semi-synthesis
of a protected baccatin III compound |
| 527 |
6,221,848 |
|
Protection
of the esophagus from chemotherapeutic or irradiation damage by gene
therapy |
| 528 |
6,221,153 |
|
Method
for producing large crystals of complex molecules |
| 529 |
6,218,434 |
|
Use
of the naturally-occurring quinones thymoquinone and dithymoquinone
as antineoplastic and cytotoxic agents |
| 530 |
6,218,377 |
|
Methods
for the administration of amifostine and related compounds |
| 531 |
6,218,367 |
|
Paclitaxel-carbohydrate
conjugates: design, synthesis and biological evaluations |
| 532 |
6,218,144 |
|
Costal2
genes and their uses |
| 533 |
6,215,000 |
|
Crystalline
complexes of baccatin III with imidazole, 2-methylimidazole or
isopropanol |
| 534 |
6,214,880 |
|
Arylsulfonanilide
ureas |
| 535 |
6,214,865 |
|
Macrocyclic
analogs and methods of their use and preparation |
| 536 |
6,214,860 |
|
Synergistic
antitumor composition containing a naphthalensulphonic acid
derivative |
| 537 |
6,214,852 |
|
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide
inhibitors of cyclin dependent kinases |
| 538 |
6,214,330 |
|
Coumarin
and related aromatic-based polymeric prodrugs |
| 539 |
6,211,167 |
|
Arylsulfonanilide
phosphates |
| 540 |
6,210,436 |
|
Implantable
members for receiving therapeutically useful compositions |
| 541 |
6,207,660 |
|
Texaphyrin
conjugates and uses thereof |
| 542 |
6,204,388 |
|
Synthesis
of epothilones, intermediates thereto and analogues thereof |
| 543 |
6,204,257 |
|
Water
soluble prodrugs of hindered alcohols |
| 544 |
6,203,813 |
|
Pharmaceutical
delivery device and method of preparation therefor |
| 545 |
6,203,551 |
|
Chamber
for applying therapeutic substances to an implant device |
| 546 |
6,201,140 |
|
7-0-ethers
of taxane derivatives |
| 547 |
6,201,072 |
|
Biodegradable
low molecular weight triblock poly(lactide-co- glycolide)
polyethylene glycol copolymers having reverse thermal gelation
properties |
| 548 |
6,201,020 |
|
Ortho-diphenol
compounds, methods and pharmaceutical compositions for inhibiting
parp |
| 549 |
6,201,001 |
|
Imidazole
antiproliferative agents |
| 550 |
6,200,992 |
|
Pharmaceutical
composition for inhibiting the growth of cancers |
| 551 |
6,200,780 |
 |
Human
interferon-.epsilon.(IFN-.epsilon.), a type I interferon |
| 552 |
6,200,598 |
|
Temperature-sensitive
liposomal formulation |
| 553 |
6,200,566 |
|
Anti-endoglin
monoclonal antibodies and their use in antiangiogenic therapy |
| 554 |
6,200,547 |
|
Magnetically
responsive compositions for carrying biologically active substances
and methods of production and use |
| 555 |
6,200,257 |
|
Catheter
with permeable hydrogel membrane |
| 556 |
6,197,981 |
|
Process
for converting 9-dihydro-13-acetylbaccatin III into taxol and
derivatives thereof |
| 557 |
6,197,785 |
|
Alkoxy-substituted
compounds, methods, and compositions for inhibiting PARP activity |
| 558 |
6,197,760 |
|
Isophosphoramide
mustard analogs and use thereof |
| 559 |
6,197,754 |
|
Suppression
of tumor growth by a mini-E1A gene |
| 560 |
6,197,325 |
|
Supplemented
and unsupplemented tissue sealants, methods of their production and
use |
| 561 |
6,197,051 |
|
Polycarbonate-polyurethane
dispersions for thromobo-resistant coatings |
| 562 |
6,194,181 |
|
Fermentative
preparation process for and crystal forms of cytostatics |
| 563 |
6,194,158 |
|
Diagnostic
assay for cancer |
| 564 |
6,191,290 |
|
Taxane
derivatives for targeted therapy of cancer |
| 565 |
6,191,170 |
|
Benzenesulfonamides
and benzamides as therapeutic agents |
| 566 |
6,190,660 |
|
Anti-endoglin
monoclonal antibodies and their use in antiangiogenic therapy |
| 567 |
6,187,936 |
|
Process
for the enzymatic kinetic resolution of 3-phenylglycidates by
transesterification with aminoalcohols |
| 568 |
6,184,395 |
|
Reaction
conditions for the cleavage of silyl ethers in the preparation of
paclitaxel(taxol.RTM.) and paclitaxel analogues |
| 569 |
6,180,802 |
|
Method
for selective protection of baccatin derivatives and its application
to taxane synthesis |
| 570 |
6,180,666 |
|
Use
of gallic acid esters to increase bioavailability of orally
administered pharmaceutical compounds |
| 571 |
6,180,633 |
|
Drug
resistance and multidrug resistance modulators |
| 572 |
6,180,355 |
|
Method
for diagnosing and treating chronic pelvic pain syndrome |
| 573 |
6,180,095 |
|
Polymeric
prodrugs of amino- and hydroxyl-containing bioactive agents |
| 574 |
6,179,817 |
|
Hybrid
coating for medical devices |
| 575 |
6,179,766 |
|
Methods
of breast cancer treatment |
| 576 |
6,177,460 |
|
Method
of treatment for cancer or viral infections |
| 577 |
6,177,456 |
|
Monohalocephalomannines
having anticancer and antileukemic activity and method of
preparation therefor |
| 578 |
6,175,023 |
|
Synthesis
of water soluble 9-dihydro-paclitaxel derivatives from
9-dihydro-13-acetylbaccatin III |
| 579 |
6,174,876 |
|
Use
of boswellic acid for treating brain tumors |
| 580 |
6,172,261 |
|
Polyamine
analogues as therapeutic and diagnostic agents |
| 581 |
6,172,205 |
|
Synthetic
process toward total synthesis of eleutherobin and its analogues and
uses thereof |
| 582 |
6,172,076 |
|
Inhibitors
of prenyl-protein transferase |
| 583 |
6,168,619 |
|
Intravascular
stent having a coaxial polymer member and end sleeves |
| 584 |
6,166,173 |
|
Biodegradable
polymers chain-extended by phosphates, compositions, articles and
methods for making and using the same |
| 585 |
6,165,509 |
|
Pegylated
drug complexed with bioadhesive polymer suitable for drug delivery
and methods relating thereto |
| 586 |
6,162,920 |
|
Taxane
derivatives having a pyridyl substituted C13 side chain, their
preparation and their use as anti-tumor agents |
| 587 |
6,162,810 |
|
Inadone
and tetralone compounds for inhibiting cell proliferation |
| 588 |
6,162,622 |
|
Preparation
of 6 hydroxy-7-deoxytaxanes using nocardioides luteus |
| 589 |
6,160,004 |
|
C-10
carbon-substituted artemisinin-like trioxane compounds having
antimalarial, antiproliferative and antitumor activities |
| 590 |
6,159,491 |
|
Prolonged
release bioadhesive vaginal gel dosage form |
| 591 |
6,159,143 |
|
Method
and device for delivery of therapeutic agents in conjunction with
isotope seed placement |
| 592 |
6,156,790 |
|
C-10
carbon-substituted artemisinin-like trioxane compounds having
antimalarial, antiproliferative and antitumor activities |
| 593 |
6,156,789 |
|
Method
for treating abnormal cell proliferation in the brain |
| 594 |
6,156,746 |
|
1,2,5-benzothiadiazepine-1,1-dioxides
with n-2 imidazolylalkyl substituents |
| 595 |
6,153,756 |
|
Soluble
prodrugs of paclitaxel |
| 596 |
6,153,655 |
|
Terminally-branched
polymeric linkers and polymeric conjugates containing the same |
| 597 |
6,153,644 |
|
Stabilized
injectable pharmaceutical compositions containing taxoid anti-neoplastic
agents |
| 598 |
6,153,585 |
|
Arylsulfonanilide
derivatives |
| 599 |
6,153,252 |
|
Process
for coating stents |
| 600 |
6,153,212 |
|
Biodegradable
terephthalate polyester-poly (phosphonate) compositions, articles,
and methods of using the same |
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
|
